(MedPage Today) — MADRID — Vericiguat (Verquvo) missed the mark for reducing heart failure (HF) hospitalizations but lowered the risk of cardiovascular death in patients with HF with reduced ejection fraction (HFrEF) but no recent decompensation…
Source link : https://www.medpagetoday.com/meetingcoverage/esc/117246
Author :
Publish date : 2025-08-31 21:26:00
Copyright for syndicated content belongs to the linked Source.
